Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665301 | 0.86 | ADORA2A (0.69) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL1665392 | 0.80 | ADORA2A (0.71) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL6690627 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL5801729 | 0.79 | ADORA2A (1.00) | ADORA2AADORA1EGFRSRCKDR | |
| Hydrochloric Acid SCHEMBL9778392 | 0.76 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| Hydrochloric Acid SCHEMBL9778348 | 0.76 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| Bromide SCHEMBL9778439 | 0.76 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| Hydrochloric Acid SCHEMBL9778422 | 0.76 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| Hydrochloric Acid SCHEMBL9778362 | 0.76 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| SCHEMBL9778803 | 0.75 | ADORA2A (0.63) | ADORA2AADORA1EGFRSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371857-B2 | Synthesis for hydroxyalkylated heterocyclic bases | VALEANT RESEARCH & DEVELOPMENT (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371857-B2 | Synthesis for hydroxyalkylated heterocyclic bases | VALEANT RESEARCH & DEVELOPMENT (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371857-B2 | Synthesis for hydroxyalkylated heterocyclic bases | VALEANT RESEARCH & DEVELOPMENT (US) | 2008-05-13 | — | — | US | disclosed |
| US-20060135768-A1 | Synthesis for hydroxyalkylated heterocyclic bases | RIBAPHARM INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-6825348-B2 | Antiviral compounds | ACADEMIA SINICA (TW) | 2004-11-30 | — | — | US | disclosed |
| WO-2004014912-A1 | IMPROVED SYNTHESIS FOR HYDROXYALKYLATED HETEROCYCLIC BASES | RIBAPHARM INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040002475-A1 | Dna genome | ACADEMIA SINICA (TW) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002475-A1 | Dna genome | DNA2, OGG1, UNG | ADORA2A 122/4885ADORA1 77/4885EGFR 2221/4885 |
| US-20060135768-A1 | Synthesis for hydroxyalkylated heterocyclic bases | TERT, HRAS, DHPS | ADORA2A 4293/4885ADORA1 4545/4885EGFR 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.